| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/2006 | EP1617846A1 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| 01/25/2006 | EP1617845A2 Compositions and methods for induction of opioid receptors |
| 01/25/2006 | EP1617844A1 Treatment of neurological conditions |
| 01/25/2006 | EP1617842A1 Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these |
| 01/25/2006 | EP1617841A1 Amino cyclobutylamide modulators of chemokine receptor activity |
| 01/25/2006 | EP1617840A2 Pyrazole-amide compounds useful as kinase inhibitors |
| 01/25/2006 | EP1617839A1 The use of azetidinecarboxamide derivatives in therapy |
| 01/25/2006 | EP1617838A1 Composition for oral administration containing alkylene dioxybenzene derivative |
| 01/25/2006 | EP1617837A1 Composition for preventing or treating allergic disease using black rice extract and its therapeutic use |
| 01/25/2006 | EP1617836A2 Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof |
| 01/25/2006 | EP1617835A2 Compounds for the treatment of metabolic disorders |
| 01/25/2006 | EP1617834A1 Lactate containing pharmaceutical composition and uses thereof |
| 01/25/2006 | EP1617833A2 Compositions and methods for treating body malodor and fungal overgrowth in mammals |
| 01/25/2006 | EP1617832A1 Compositions for affecting weight loss |
| 01/25/2006 | EP1617831A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse |
| 01/25/2006 | EP1617830A2 Esterified fatty acid composition |
| 01/25/2006 | EP1617829A2 Yeast ectopically expressing abnormally processed proteins and uses therefor |
| 01/25/2006 | EP1617827A1 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances |
| 01/25/2006 | EP1617826A2 The dispersible alendronate microparticle formulation |
| 01/25/2006 | EP1617825A2 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom |
| 01/25/2006 | EP1617824A1 Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof |
| 01/25/2006 | EP1617821A1 Chrono delivery formulations and method of treating atrial fibrillation |
| 01/25/2006 | EP1617818A1 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| 01/25/2006 | EP1617817A2 Oral spray to reduce cold symptoms and duration of same |
| 01/25/2006 | EP1617815A2 Process for making gel films |
| 01/25/2006 | EP1617810A2 Methods for preparation and use of 1alpha,24(s)-dihydroxyvitamin d2 |
| 01/25/2006 | EP1617807A2 Substituted 1,4-diazepines and uses thereof |
| 01/25/2006 | EP1617806A2 Selective spirocyclic glucocorticoid receptor modulators |
| 01/25/2006 | EP1617805A2 Methods of preventing or treating respiratory conditions |
| 01/25/2006 | EP1617803A2 Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| 01/25/2006 | EP1617785A2 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem |
| 01/25/2006 | EP1617733A1 Preparations for oral administration containing physiologically active fatty acids and oligomer proanthocyanidin |
| 01/25/2006 | EP1617731A2 Use of allicin as preservative, as disinfectant, as antimicrobial or as biocidal agent |
| 01/25/2006 | EP1617724A1 Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| 01/25/2006 | EP1513826B1 New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents |
| 01/25/2006 | EP1506179B1 Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
| 01/25/2006 | EP1490363B1 Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone |
| 01/25/2006 | EP1465620A4 Novel composition of carvedilol |
| 01/25/2006 | EP1450787A4 Formulations and methods for treatment or amelioration of inflammatory conditions |
| 01/25/2006 | EP1392241A4 System for osmotic delivery of pharmaceutically active agents |
| 01/25/2006 | EP1372627B1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/25/2006 | EP1347965B1 New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof |
| 01/25/2006 | EP1267901B1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/25/2006 | EP1255746B1 Oxy- and amino-substituted tetrahydrofuryl derivatives with antimour activity |
| 01/25/2006 | EP1245232B1 Oral solid preparation |
| 01/25/2006 | EP1235825B1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 01/25/2006 | EP1224189B1 Condensed dihydroquinolinone derivatives for inhibiting mrp1 |
| 01/25/2006 | EP1212318B1 Substituted indolinones as tyrosine kinase inhibitors |
| 01/25/2006 | EP1158950B1 Anticonvulsant derivatives useful in treating essential tremor |
| 01/25/2006 | EP1144000B1 New dialysis method |
| 01/25/2006 | EP1135127B1 New pharmaceutical composition and the process for its preparation |
| 01/25/2006 | EP1082961B1 Sleep inducing agent comprising prostaglandin derivatives |
| 01/25/2006 | EP1080202B1 Convection-enhanced delivery of aav vectors encoding aadc |
| 01/25/2006 | EP1051495B1 Recombinant mistletoe lectines |
| 01/25/2006 | EP1001757B1 Fast-acting analgesic |
| 01/25/2006 | EP0987022B1 Conagenin for the treatment of ulcerous colitis and/or crohn's disease |
| 01/25/2006 | EP0980427B1 Use of ulip proteins in the diagnosis and therapy of cancer and paraneoplastic neurological syndromes |
| 01/25/2006 | EP0914158B2 Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| 01/25/2006 | EP0869788B1 Compositions for the treatment of renal failure, comprising l-carnosine |
| 01/25/2006 | EP0813403B1 Stable water-in-oil emulsion system |
| 01/25/2006 | EP0759781B1 Compositions for treating and preventing atherosclerosis |
| 01/25/2006 | EP0759694B1 Method for in vivo delivery of therapeutic agents via liposomes |
| 01/25/2006 | EP0697872B1 Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| 01/25/2006 | CN1726285A Methods and compositions for immunization against HIV |
| 01/25/2006 | CN1726222A Novel semisynthetic macrolide antibiotics of the azalide series |
| 01/25/2006 | CN1726218A Pyrrolopyrimidine derivatives |
| 01/25/2006 | CN1726217A Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/25/2006 | CN1726216A C-6 modified indazolylpyrrolotriazines |
| 01/25/2006 | CN1726215A [1,7]naphthyridines as PDE4 inhibitors |
| 01/25/2006 | CN1726214A Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
| 01/25/2006 | CN1726213A Imidazoquinoline derivatives as adenosine A3 receptor ligands |
| 01/25/2006 | CN1726211A Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
| 01/25/2006 | CN1726210A Novel compounds having selective inhibiting effect at GSK3 |
| 01/25/2006 | CN1726208A Complexes of E-2-methoxy-N-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
| 01/25/2006 | CN1726207A Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 01/25/2006 | CN1726206A Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 01/25/2006 | CN1726204A Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors |
| 01/25/2006 | CN1726202A Crystalline escitalopram hydrobromide and methods for preparing the same |
| 01/25/2006 | CN1726199A Novel 2,4-diamino-1,3,5-triazine derivative |
| 01/25/2006 | CN1726198A Compounds, compositions, and methods |
| 01/25/2006 | CN1726197A 5-substituted-pyrazine or -pyridine glucokinase activators |
| 01/25/2006 | CN1726196A Pyrazine-based tubulin inhibitors |
| 01/25/2006 | CN1726194A Novel compounds |
| 01/25/2006 | CN1726193A Heterocyclic selective androgen receptor modulators and methods of use thereof |
| 01/25/2006 | CN1726191A Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| 01/25/2006 | CN1726190A Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| 01/25/2006 | CN1726189A Novel MCH receptor antagonists |
| 01/25/2006 | CN1726188A Treating syndrome X with substituted tetralins and indanes |
| 01/25/2006 | CN1726187A Substituted tetralins and indanes and their use |
| 01/25/2006 | CN1726185A Formulations comprising selective androgen receptor modulators and using method thereof |
| 01/25/2006 | CN1726062A Liquid pharmaceutical formulations containing 3.7-diazabicyclo[3,3,1]nonane compounds and methods of treatment relating to arrhythmic events |
| 01/25/2006 | CN1726049A Compositions, methods, and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
| 01/25/2006 | CN1726048A Gastric acid secretion inhibiting composition |
| 01/25/2006 | CN1726043A Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
| 01/25/2006 | CN1726042A Benzo[d]azepine derivatives for the treatment of neurological disorders |
| 01/25/2006 | CN1726041A Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome p450, such as protease inhibitors |
| 01/25/2006 | CN1726040A Use of dihydroimidazolones for the treatment of epilepsy in dogs |
| 01/25/2006 | CN1726039A Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| 01/25/2006 | CN1726038A Tiotropium containing HFC solution formulations |
| 01/25/2006 | CN1726037A Treatment of headache with antipsychotics delivered by inhalation |